Kodiak Sciences Inc. (KOD) experienced a significant pre-market surge of 5.56% on Friday.
The sharp increase appears to be driven by bullish analyst actions, as multiple firms raised their price targets for the biopharmaceutical company. H.C. Wainwright increased its target to $58 from $38, while Jefferies raised its target to $56 from $39. These substantial upward revisions signal improved analyst confidence and likely prompted investor optimism in the pre-market session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments